SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-017790
Filing Date
2023-11-06
Accepted
2023-11-06 17:15:41
Documents
82
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q icpt-20230930x10q.htm   iXBRL 10-Q 2501585
2 EX-31.1 icpt-20230930xex31d1.htm EX-31.1 9882
3 EX-31.2 icpt-20230930xex31d2.htm EX-31.2 9865
4 EX-32.1 icpt-20230930xex32d1.htm EX-32.1 10352
  Complete submission text file 0001558370-23-017790.txt   10416261

Data Files

Seq Description Document Type Size
5 EX-101.SCH icpt-20230930.xsd EX-101.SCH 59767
6 EX-101.CAL icpt-20230930_cal.xml EX-101.CAL 90235
7 EX-101.DEF icpt-20230930_def.xml EX-101.DEF 238390
8 EX-101.LAB icpt-20230930_lab.xml EX-101.LAB 528189
9 EX-101.PRE icpt-20230930_pre.xml EX-101.PRE 417715
76 EXTRACTED XBRL INSTANCE DOCUMENT icpt-20230930x10q_htm.xml XML 2134325
Mailing Address 305 MADISON AVENUE MORRISTOWN NJ 07960
Business Address 305 MADISON AVENUE MORRISTOWN NJ 07960 646-747-1000
INTERCEPT PHARMACEUTICALS, INC. (Filer) CIK: 0001270073 (see all company filings)

IRS No.: 223868459 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35668 | Film No.: 231380780
SIC: 2834 Pharmaceutical Preparations